Explainer

What does FDA's Category 2 mean for BPC-157?

Short answer · as of 2026-10-05

Category 2 is an FDA interim category for bulk drug substances that FDA says raise safety concerns for compounding. FDA's page on those substances (updated Apr. 22, 2026) lists BPC-157 in its table of substances “nominated but withdrawn,” citing possible immunogenicity for certain routes and limited safety information. FDA's briefing document for the July 2026 advisory committee proposed that BPC-157 and six other peptides not be included on the 503A bulks list. Outlets report the panel backed six of the seven anyway, but its votes are nonbinding.

By Peptide Industry Gossip · Published · General explanation, not legal or medical advice. Disclaimer.

The three interim categories

FDA uses three interim categories for bulk drug substances nominated for use in compounding under section 503A while the 503A bulks list is unfinished. The categories describe FDA's enforcement stance toward compounders. Read FDA's page for the exact conditions.

  • Category 1: substances FDA considers eligible for compounding under specified conditions while it evaluates them for the list.
  • Category 2: substances FDA identified as raising significant safety risks. FDA publishes safety summaries for them.
  • Category 3: substances nominated without enough supporting information for FDA to evaluate them.

What FDA's BPC-157 entry says

FDA's page lists BPC-157 in its “bulk drug substances nominated but withdrawn” table. It says compounded drugs containing BPC-157 may pose a risk of immunogenicity for certain routes of administration, and it points to peptide-related impurities. FDA says it lacks enough information to know whether the drug would cause harm. The page is updated Apr. 22, 2026 and states that FDA uses a Category 2 system under its interim policies.

We have not confirmed what the “withdrawn” listing means for BPC-157's current status in FDA's evaluation. Check FDA's page for the current wording.

Where the July 2026 panel vote stands

FDA's meeting page confirms a July 23-24, 2026 advisory committee meeting on seven peptides. FDA's briefing document for the meeting proposed that none of the seven, BPC-157 included, be included on the 503A bulks list, and asked the committee whether it agreed. Outlets report the panel instead backed six of the seven for the list and voted against one. The votes are nonbinding, and a formal rule would be needed before pharmacies could rely on the list. The FDA pages we retrieved on Oct. 5 did not show a category change for BPC-157.

What a category does not mean

  • It describes FDA's stance toward compounding under section 503A. It is not a court ruling and not a finding about any one product.
  • It is separate from the warning letters to research-chemical sellers in our index, which cite sections 301(d) and 505(a) of the Act.
  • Categories can change. Treat what you read here as true on the date shown, then check FDA.

Sources

Quotes are from the FDA documents above, retrieved Oct. 5, 2026. FDA can revise those pages. See something wrong? Request a correction.

Related